Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.3063 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Ho-Chang Kuo und 21 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Chang Gung University, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Mucocutaneous Lymph Node Syndrome, Immunoglobulins, Intravenous, Aspirin, Coronary Artery Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Importance Aspirin (acetylsalicylic acid) and intravenous immunoglobulin (IVIG) are standard treatments for Kawasaki disease (KD) to reduce coronary artery lesions (CALs). However, the optimal duration and dosage of aspirin remain inconsistent across hospitals. The absence of large-scale, multicenter randomized clinical trials hinders a clear understanding of the effectiveness of high-dose aspirin.
Objective
To evaluate the effectiveness of IVIG alone compared with IVIG combined with high-dose aspirin as the active interventional therapy for KD and to compare treatment effectiveness across various KD subgroups. Design, Setting, and Participants In this prospective, evaluator-blinded, multicenter noninferiority randomized clinical trial, children (aged <6 years) who had been diagnosed with KD according to American Heart Association criteria were recruited from 5 medical centers in Taiwan and were enrolled between September 1, 2016, and August 31, 2018, with follow-up assessments at 6 weeks and 6 months after treatment. Data were analyzed between January 23, 2023, and January 29, 2024.
Intervention
The standard group received IVIG (2 g/kg) plus high-dose aspirin (80-100 mg/kg per day) until fever subsided for 48 hours. The intervention group received IVIG (2 g/kg) alone. Main Outcomes and Measures The primary outcome was the occurrence of CALs at 6 weeks. The noninferiority margin was set at 10%. Data analysis was performed using χ 2 tests for categorical variables; independent t tests for continuous, normally distributed variables; generalized estimating equations for variables without specific distributions at multiple time points; and repeated-measures analysis of variance for continuous variables at multiple time points.
Results
The final cohort consisted of 134 patients with KD (mean [SD] age, 1.8 [1.3] years; 82 males [61.2%]), with matched age, weight, height, and sex distributions in 2 groups. Overall, in the IVIG plus aspirin group, among 69 patients, CAL occurrence decreased from 9 (13.0%) at baseline to 2 (2.9%) at 6 weeks and to 1 (1.4%) at 6 months. In the IVIG-only group, among 65 patients, CAL occurrence decreased from 7 (10.8%) at diagnosis to 1 (1.5%) at 6 weeks and to 2 (3.1%) at 6 months. No statistically significant differences in CAL frequency were observed between the 2 groups (0.7 percentage points [95% CI, −4.5 to 5.8 percentage points]; P = .65). There were also no significant differences in the treatment or prophylactic effect. Conclusions and Relevance This randomized clinical trial demonstrated the noninferiority of IVIG alone compared with IVIG plus aspirin, with a noninferiority margin set at 10%. The findings suggest that addition of high-dose aspirin during initial IVIG treatment is not clinically meaningful for CAL reduction in children with KD. Future studies on IVIG treatment alone for CAL reduction in KD across diverse racial and ethnic groups, beyond the Asian population, may be necessary to confirm minimal racial and ethnic variability and the broad applicability of these findings. Trial Registration ClinicalTrials.gov Identifier: NCT02951234
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Department of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan.
Förderung
- NCATS NIH HHS
Zitieren
APA
Kuo, H. C., Lin, M. C., Kao, C. C., Weng, K. P., Ding, Y., Han, Z., Chen, C. J., Jan, S. L., Chien, K. J., Ko, C. H., Lin, C. Y., Lei, W. T., Guo, M. M., Yang, K. D., Sylvester, K. G., Whitin, J. C., Tian, L., Chubb, H., Ceresnak, S. R., …, & Ling, X. B. (2025). Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.3063
Vancouver
Kuo HC, Lin MC, Kao CC, Weng KP, Ding Y, Han Z, et al. Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.3063
BibTeX
@article{Kuo2025,
author = {Kuo, Ho-Chang and Lin, Ming-Chih and Kao, Chung-Chih and Weng, Ken-Pen and Ding, Yun and Han, Zhi and Chen, Chih-Jung and Jan, Sheng-Ling and Chien, Kuang-Jen and Ko, Chun-Hsiang and Lin, Chien-Yu and Lei, Wei-Te and Guo, Mindy Ming-Huey and Yang, Kuender D and Sylvester, Karl G and Whitin, John C and Tian, Lu and Chubb, Henry and Ceresnak, Scott R and McElhinney, Doff and Cohen, Harvey J and Ling, Xuefeng B},
title = {Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.3063}
}
EUVIMED